# US 2021/0260150 A1 · Dry powder formulation of caveolin-1 peptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0260150 A1
- Document ID: US20210260150A1
- Status: Published application
- Kind: A1
- Application number: 17/274,666
- Filed: 2019-09-10
- Published: 2021-08-26
- Earliest claimed: 2018-09-10
- Assignees: Board of Regents, The University of Texas System; Lung Therapeutics, Inc.
- Applicants: Board of Regents, the University of Texas System; Lung Therapeutics, Inc.
- Inventors: Robert O. WILLIAMS, III; Alan B. WATTS; Yajie ZHANG; Sawittree SAHAKIJPIJARN; Dale CHRISTENSEN; John J. KOLENG
- Web page: https://patentgrep.com/patent/US20210260150A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 9/00: Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 7/06: having 5 to 11 amino acids
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

## Claims

### Claim 1

A pharmaceutical composition comprising a dry powder of a peptide, said peptide comprising a sequence of anyone of SEQ ID NOs: 2-20.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide is 7-20 amino acids in length.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the peptide comprises at least one amino acid added to the N-terminus of a peptide of SEQ ID NO: 2.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the peptide comprises at least one amino acid added to the C-terminus of a peptide of SEQ ID NO: 2.

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3, wherein the peptide comprises at least one amino acid added to the N-terminus and the C-terminus of a peptide of SEQ ID NO: 2.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises L-amino acids.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises D-amino acids.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises both L- and D-amino acids.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises at least one deuterated residue.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises at least one non-standard amino acid.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the peptide comprises 2 non-standard amino acids.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the non-standard amino acid is ornithine.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises a N-terminal modification.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises a C-terminal modification.

### Claim 16 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises a N- and C-terminal modification.

### Claim 17 (depends on 14)

The pharmaceutical composition of claim 14, wherein the N-terminal modification is acylation.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein the C-terminal modification is amidation.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1, the peptide comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 20 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 21 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 6.

### Claim 22 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 9.

### Claim 23 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 5.

### Claim 24 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 7.

### Claim 25 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 26 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 11.

### Claim 27 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 12.

### Claim 28 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 13.

### Claim 29 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 14.

### Claim 30 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 15.

### Claim 31 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 16.

### Claim 32 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17.

### Claim 33 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 18.

### Claim 34 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 19.

### Claim 35 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 10.

### Claim 36 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 20.

### Claim 37 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a cell-penetrating peptide (CPP).

### Claim 38 (depends on 37)

The pharmaceutical composition of claim 37, wherein the CPP comprises an amino acid sequence selected from the group comprising: GRKKRRQRRRPPQ (SEQ ID NO: 23), RQIKIWFQNRRMKWKK (SEQ ID NO: 24), and GIGAVLKVLTTGLPALISWIKRKRQQ (SEQ ID NO: 25).

### Claim 39 (depends on 1)

The pharmaceutical composition of claim 1, wherein the peptide comprises at least two repeats of a sequence of any one of SEQ ID NOs: 2-20.

### Claim 40 (depends on 39)

The pharmaceutical composition of claim 39, wherein the at least two repeats have identical amino acid sequences.

### Claim 41 (depends on 39)

The pharmaceutical composition of claim 39, wherein the at least two repeats have different amino acid sequences.

### Claim 42 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder is produced by a milling process.

### Claim 43 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder is produced by a spray-drying process.

### Claim 44 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder is produced by air jet milling.

### Claim 45 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder is produced by ball milling.

### Claim 46 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder is produced by wet milling.

### Claim 47 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder comprises less than 10% (by weight) of water.

### Claim 48 (depends on 1)

The pharmaceutical composition of claim 1, wherein the dry powder comprises less than 1% (by weight) of water.

### Claim 49 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is essentially excipient free.

### Claim 50 (depends on 49)

The pharmaceutical composition of claim 49, wherein the pharmaceutical composition is excipient free.

### Claim 51 (depends on 1)

The pharmaceutical composition claim 1, wherein the pharmaceutical composition is formulated for lung delivery.

### Claim 52 (depends on 51)

The pharmaceutical composition of claim 51, wherein the pharmaceutical composition is formulated for dry powder inhalation.

### Claim 53 (depends on 51)

The pharmaceutical composition of claim 51, wherein the pharmaceutical composition is formulated for inhalation pressurized metered dose inhalation.

### Claim 54 (depends on 1)

The pharmaceutical composition claim 1, wherein the pharmaceutical composition is formulated for oral administration, topical administration or injection.

### Claim 55 (depends on 1)

A nebulizer device comprising a pharmaceutical composition of claim 1.

### Claim 56 (depends on 1)

A method of treating a subject comprising administering to the subject an effective amount of a pharmaceutical composition of claim 1 to the subject.

### Claim 57 (depends on 56)

The method of claim 56, wherein the subject has an inflammatory disorder.

### Claim 58 (depends on 56)

The method of claim 56, wherein the subject has a fibrotic condition.

### Claim 59 (depends on 56)

The method of claim 56, wherein the subject has pulmonary inflammation, acute lung injury, lung infection or lung.

### Claim 60 (depends on 59)

The method of claim 59, wherein the subject has pulmonary inflammation.

### Claim 61 (depends on 56)

The method of claim 56, wherein the subject has chronic obstructive pulmonary disorder (COPD).

### Claim 62 (depends on 56)

The method of claim 56, wherein the subject has an acute lung injury or infection.

### Claim 63 (depends on 56)

The method of claim 56, wherein the subject has a lung infection.

### Claim 64 (depends on 56)

The method of claim 56, wherein the subject has a chemical-induced lung injury.

### Claim 65 (depends on 56)

The method of claim 56, wherein the subject has plastic bronchitis.

### Claim 66 (depends on 56)

The method of claim 56, wherein the subject has asthma.

### Claim 67 (depends on 56)

The method of claim 56, wherein the subject has acute respiratory distress syndrome (ARDS).

### Claim 68 (depends on 56)

The method of claim 56, wherein the subject has inhalational smoke induced acute lung injury (ISALI).

### Claim 69 (depends on 56)

The method of claim 56, wherein the subject has bronchiolitis.

### Claim 70 (depends on 56)

The method of claim 56, wherein the subject has bronchiolitis obliterans.

### Claim 71 (depends on 56)

The method of claim 56, wherein the lung disease is a fibrotic condition of the lungs.

### Claim 72 (depends on 56)

The method of claim 56, wherein the lung disease is interstitial lung disease.

### Claim 73 (depends on 56)

The method of claim 56, wherein the lung disease is Idiopathic Pulmonary Fibrosis (IPF) or lung scarring.

### Claim 74 (depends on 56)

The method of claim 56, wherein the administering comprises dry powder inhalation.

### Claim 75 (depends on 56)

The method of claim 56, wherein the administering comprises nebulizing a solution comprising the variant polypeptide.

### Claim 76 (depends on 56)

The method of claim 56, further comprising administering at least one additional anti-fibrotic therapeutic.

### Claim 77 (depends on 76)

The method of claim 76, wherein the at least one additional anti-fibrotic is NSAID, steroid, DMARD, immunosuppressive, biologic response modulators, or bronchodilator.

### Claim 78 (depends on 56)

The method of claim 56, wherein the subject is a human.

### Claim 79

A pharmaceutical composition, comprising a peptide of SEQ ID Nos: 2-20 formulated a milled dry powder having a respirable particle size.

### Claim 80 (depends on 79)

A method of treating a subject comprising administering an effective amount of a composition of claim 79 to the subject by inhalation.
